Neos Therapeutics (NEOS) Issues Earnings Results, Misses Expectations By $0.03 EPS

Share on StockTwits

Neos Therapeutics (NASDAQ:NEOS) posted its quarterly earnings data on Friday. The company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.03), MarketWatch Earnings reports. Neos Therapeutics had a negative return on equity of 586.25% and a negative net margin of 164.40%. The company had revenue of $12.50 million for the quarter, compared to analysts’ expectations of $14.80 million.

NASDAQ NEOS traded up $0.01 during trading hours on Friday, reaching $2.59. 651,079 shares of the company were exchanged, compared to its average volume of 621,268. Neos Therapeutics has a 1 year low of $2.27 and a 1 year high of $11.69. The company has a market capitalization of $83.38 million, a PE ratio of -0.97 and a beta of 0.44.

In related news, Director Alan L. Heller acquired 43,478 shares of the firm’s stock in a transaction that occurred on Thursday, November 8th. The stock was acquired at an average price of $2.30 per share, for a total transaction of $99,999.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 5.40% of the company’s stock.

NEOS has been the subject of a number of research analyst reports. ValuEngine upgraded shares of Neos Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, September 24th. Cantor Fitzgerald restated a “buy” rating and set a $20.00 price objective on shares of Neos Therapeutics in a report on Wednesday, August 8th. Zacks Investment Research upgraded shares of Neos Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 11th. Finally, Wells Fargo & Co decreased their price objective on shares of Neos Therapeutics from $14.00 to $11.00 and set a “buy” rating for the company in a report on Thursday, August 9th. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $15.50.

TRADEMARK VIOLATION NOTICE: “Neos Therapeutics (NEOS) Issues Earnings Results, Misses Expectations By $0.03 EPS” was originally reported by Ticker Report and is the property of of Ticker Report. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://www.tickerreport.com/banking-finance/3929310/neos-therapeutics-neos-issues-earnings-results-misses-expectations-by-0-03-eps.html.

Neos Therapeutics Company Profile

Neos Therapeutics, Inc, a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its product candidates are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms.

Featured Story: What is Cost of Debt?

Earnings History for Neos Therapeutics (NASDAQ:NEOS)

Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Intra-Cellular Therapies  Downgraded by Zacks Investment Research
Intra-Cellular Therapies Downgraded by Zacks Investment Research
Astronics  Upgraded to Hold by ValuEngine
Astronics Upgraded to Hold by ValuEngine
Cabot  Upgraded by ValuEngine to “Sell”
Cabot Upgraded by ValuEngine to “Sell”
Global Blood Therapeutics  Downgraded by ValuEngine to Buy
Global Blood Therapeutics Downgraded by ValuEngine to Buy
Head-To-Head Comparison: Anthem  and Advanzeon Solutions
Head-To-Head Comparison: Anthem and Advanzeon Solutions
ADDvantage Technologies Group  & W W Grainger  Head-To-Head Contrast
ADDvantage Technologies Group & W W Grainger Head-To-Head Contrast


Leave a Reply

© 2006-2018 Ticker Report